ScoreWhy is Jagsonpal Pharmaceuticals Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 8.85% over the last 5 years
2
Negative results in Mar 26
- PBT LESS OI(Q) At Rs 8.59 cr has Fallen at -23.9% (vs previous 4Q average)
- PAT(Q) At Rs 8.76 cr has Fallen at -17.8% (vs previous 4Q average)
- NET SALES(Q) At Rs 64.20 cr has Fallen at -8.8% (vs previous 4Q average)
3
With ROE of 17.7, it has a Very Expensive valuation with a 5.6 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -3.10%, its profits have risen by 15.1% ; the PEG ratio of the company is 2.3
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jagsonpal Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
-2.63%
-0.07
38.41%
Sensex
-3.59%
-0.27
13.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.85%
EBIT Growth (5y)
22.01%
EBIT to Interest (avg)
33.43
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
1.31
Tax Ratio
25.10%
Dividend Payout Ratio
58.85%
Pledged Shares
0
Institutional Holding
2.67%
ROCE (avg)
36.15%
ROE (avg)
16.16%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
34
Price to Book Value
5.56
EV to EBIT
25.82
EV to EBITDA
21.62
EV to Capital Employed
12.26
EV to Sales
4.37
PEG Ratio
2.29
Dividend Yield
1.18%
ROCE (Latest)
44.66%
ROE (Latest)
17.66%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-6What is not working for the Company
PBT LESS OI(Q)
At Rs 8.59 cr has Fallen at -23.9% (vs previous 4Q average
PAT(Q)
At Rs 8.76 cr has Fallen at -17.8% (vs previous 4Q average
NET SALES(Q)
At Rs 64.20 cr has Fallen at -8.8% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is not working for Jagsonpal Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 8.59 cr has Fallen at -23.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 11.29 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 8.76 cr has Fallen at -17.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 10.66 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 64.20 cr has Fallen at -8.8% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 70.40 CrMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 3.17 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
